Form 4: Amicus Therapeutics CEO Bradley Campbell Reports Stock Disposal
SEC Form 4
Bradley Campbell, President and CEO of Amicus Therapeutics, disposed of 13,375 shares of common stock on March 15, 2024, to cover tax obligations.
Summary
- On March 15, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, disposed of 13,375 shares of common stock.
- The transaction was executed at a price of $11.48 per share.
- Following the transaction, Campbell directly owns 886,654 shares of Amicus Therapeutics.
- The disposal was related to covering tax obligations.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a standard transaction. The disposal of shares to cover tax obligations is a common practice and doesn't necessarily indicate a negative outlook on the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like CEOs and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The transaction could have a minor impact on shareholders if it leads to a slight decrease in the stock price due to the increased supply of shares.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of the stock disposal transaction |
| 03/19/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.